The long-term data on standard-dose GLP-1 medications continues to be reassuring most cardiovascular and renal outcome trials now extend out 3 to 5 years
Weight loss with GLP-1s has been shown to reduce the risk of conditions like heart disease, diabetes, and metabolic syndrome
Semaglutide or tirzepatide side-effect review Medication and supplement reconciliation Meal-size, nutrition, hydration, and bowel-pattern review Assessment of whether urgent care or gastroenterology referral is needed Coordination with the patients primary-care or digestive-health clinician This page does not claim that Green Relief Health is a gastroenterology practice, performs endoscopy, provides emergency care, or offers every test described
References Abrahami D, DAndrea E, Yin H, Kim SC, Paik JM, Wexler D, et al
You can read the full article at LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism
Enteroendocrine K and L cells in healthy and type 2 diabetic individuals
